Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation

Antonio Bisignani; Luigi Pannone; Vincenzo Miraglia; Juan Sieira; Saverio Iacopino; Gezim Bala; Erwin Ströker; Ingrid Overeinder; Alexandre Almorad; Anaïs Gauthey; Cinzia Monaco; Gaetano Paparella; Thiago Guimarães Osório; Antonio Sorgente; Luc Jordaens; Pedro Brugada; Gian-Battista Chierchia; Carlo de Asmundis

doi:10.1111/pace.14495

Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation

Antonio Bisignani, Luigi Pannone, Vincenzo Miraglia, Juan Sieira, Saverio Iacopino, Gezim Bala, Erwin Ströker, Ingrid Overeinder, Alexandre Almorad, Anaïs Gauthey, Cinzia Monaco, Gaetano Paparella, Thiago Guimarães Osório, Antonio Sorgente, Luc Jordaens, Pedro Brugada, Gian-Battista Chierchia, Carlo de Asmundis

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

BACKGROUND: Left atrial posterior wall isolation (LAPWI) is often performed in addition to pulmonary vein isolation (PVI) in the setting of persistent atrial fibrillation (AF) ablation. The aim of this study was to evaluate the feasibility and safety of a new cryoballoon ablation system in achieving PVI + LAPWI isolation.

METHODS: The study was a prospective, non-randomized, single center study. Forty consecutive patients, undergoing PVI + LAPWI with the novel POLARx™, were compared to 40 consecutive patients who underwent the same procedure with the established Arctic Front Advance PRO™.

RESULTS: Acute isolation was achieved in all PVs in both groups and left posterior wall isolation (LAPWI) was achieved in 38 patients (95%) in the POLARx group and in 36 patients (90%) in Arctic Front group. Procedural outcomes were similar between both groups, except for lower temperatures during cryoenergy in the POLARx group, for both pulmonary vein isolation (PVI) and LAPWI.

CONCLUSION: LAPWI + PVI with the novel POLARx™ Cryoballoon is feasible and safe; the results are comparable with the Arctic Front Advance PRO™ system.

Original language	English
Pages (from-to)	605-611
Number of pages	7
Journal	Pacing and Clinical Electrophysiology
Volume	45
Issue number	5
Early online date	2022
DOIs	https://doi.org/10.1111/pace.14495
Publication status	Published - May 2022

Bibliographical note

Keywords

systematic review
cryoballoon
left atrial posterior wall ablation
persistent atrial fibrillation
pulmonary vein isolation

Access to Document

10.1111/pace.14495

Cite this

Bisignani, A., Pannone, L., Miraglia, V., Sieira, J., Iacopino, S., Bala, G., Ströker, E., Overeinder, I., Almorad, A., Gauthey, A., Monaco, C., Paparella, G., Osório, T. G., Sorgente, A., Jordaens, L., Brugada, P., Chierchia, G.-B., & Asmundis, C. D. (2022). Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation. Pacing and Clinical Electrophysiology, 45(5), 605-611. https://doi.org/10.1111/pace.14495

@article{4c10a7873ca7425ca1dfb2f135d2d04d,

title = "Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation",

abstract = "BACKGROUND: Left atrial posterior wall isolation (LAPWI) is often performed in addition to pulmonary vein isolation (PVI) in the setting of persistent atrial fibrillation (AF) ablation. The aim of this study was to evaluate the feasibility and safety of a new cryoballoon ablation system in achieving PVI + LAPWI isolation.METHODS: The study was a prospective, non-randomized, single center study. Forty consecutive patients, undergoing PVI + LAPWI with the novel POLARx{\texttrademark}, were compared to 40 consecutive patients who underwent the same procedure with the established Arctic Front Advance PRO{\texttrademark}.RESULTS: Acute isolation was achieved in all PVs in both groups and left posterior wall isolation (LAPWI) was achieved in 38 patients (95%) in the POLARx group and in 36 patients (90%) in Arctic Front group. Procedural outcomes were similar between both groups, except for lower temperatures during cryoenergy in the POLARx group, for both pulmonary vein isolation (PVI) and LAPWI.CONCLUSION: LAPWI + PVI with the novel POLARx{\texttrademark} Cryoballoon is feasible and safe; the results are comparable with the Arctic Front Advance PRO{\texttrademark} system.",

keywords = "systematic review, cryoballoon, left atrial posterior wall ablation, persistent atrial fibrillation, pulmonary vein isolation",

author = "Antonio Bisignani and Luigi Pannone and Vincenzo Miraglia and Juan Sieira and Saverio Iacopino and Gezim Bala and Erwin Str{\"o}ker and Ingrid Overeinder and Alexandre Almorad and Ana{\"i}s Gauthey and Cinzia Monaco and Gaetano Paparella and Os{\'o}rio, {Thiago Guimar{\~a}es} and Antonio Sorgente and Luc Jordaens and Pedro Brugada and Gian-Battista Chierchia and Asmundis, {Carlo de}",

note = "{\textcopyright} 2022 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals LLC.",

year = "2022",

month = may,

doi = "10.1111/pace.14495",

language = "English",

volume = "45",

pages = "605--611",

journal = "Pacing and Clinical Electrophysiology",

issn = "0147-8389",

publisher = "Wiley-Blackwell",

number = "5",

}

Bisignani, A, Pannone, L, Miraglia, V, Sieira, J, Iacopino, S, Bala, G , Ströker, E , Overeinder, I , Almorad, A , Gauthey, A , Monaco, C , Paparella, G , Osório, TG , Sorgente, A , Jordaens, L , Brugada, P , Chierchia, G-B & Asmundis, CD 2022, 'Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation', Pacing and Clinical Electrophysiology, vol. 45, no. 5, pp. 605-611. https://doi.org/10.1111/pace.14495

TY - JOUR

T1 - Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation

AU - Bisignani, Antonio

AU - Pannone, Luigi

AU - Miraglia, Vincenzo

AU - Sieira, Juan

AU - Iacopino, Saverio

AU - Bala, Gezim

AU - Ströker, Erwin

AU - Overeinder, Ingrid

AU - Almorad, Alexandre

AU - Gauthey, Anaïs

AU - Monaco, Cinzia

AU - Paparella, Gaetano

AU - Osório, Thiago Guimarães

AU - Sorgente, Antonio

AU - Jordaens, Luc

AU - Brugada, Pedro

AU - Chierchia, Gian-Battista

AU - Asmundis, Carlo de

PY - 2022/5

Y1 - 2022/5

N2 - BACKGROUND: Left atrial posterior wall isolation (LAPWI) is often performed in addition to pulmonary vein isolation (PVI) in the setting of persistent atrial fibrillation (AF) ablation. The aim of this study was to evaluate the feasibility and safety of a new cryoballoon ablation system in achieving PVI + LAPWI isolation.METHODS: The study was a prospective, non-randomized, single center study. Forty consecutive patients, undergoing PVI + LAPWI with the novel POLARx™, were compared to 40 consecutive patients who underwent the same procedure with the established Arctic Front Advance PRO™.RESULTS: Acute isolation was achieved in all PVs in both groups and left posterior wall isolation (LAPWI) was achieved in 38 patients (95%) in the POLARx group and in 36 patients (90%) in Arctic Front group. Procedural outcomes were similar between both groups, except for lower temperatures during cryoenergy in the POLARx group, for both pulmonary vein isolation (PVI) and LAPWI.CONCLUSION: LAPWI + PVI with the novel POLARx™ Cryoballoon is feasible and safe; the results are comparable with the Arctic Front Advance PRO™ system.

AB - BACKGROUND: Left atrial posterior wall isolation (LAPWI) is often performed in addition to pulmonary vein isolation (PVI) in the setting of persistent atrial fibrillation (AF) ablation. The aim of this study was to evaluate the feasibility and safety of a new cryoballoon ablation system in achieving PVI + LAPWI isolation.METHODS: The study was a prospective, non-randomized, single center study. Forty consecutive patients, undergoing PVI + LAPWI with the novel POLARx™, were compared to 40 consecutive patients who underwent the same procedure with the established Arctic Front Advance PRO™.RESULTS: Acute isolation was achieved in all PVs in both groups and left posterior wall isolation (LAPWI) was achieved in 38 patients (95%) in the POLARx group and in 36 patients (90%) in Arctic Front group. Procedural outcomes were similar between both groups, except for lower temperatures during cryoenergy in the POLARx group, for both pulmonary vein isolation (PVI) and LAPWI.CONCLUSION: LAPWI + PVI with the novel POLARx™ Cryoballoon is feasible and safe; the results are comparable with the Arctic Front Advance PRO™ system.

KW - systematic review

KW - cryoballoon

KW - left atrial posterior wall ablation

KW - persistent atrial fibrillation

KW - pulmonary vein isolation

UR - http://www.scopus.com/inward/record.url?scp=85128542399&partnerID=8YFLogxK

U2 - 10.1111/pace.14495

DO - 10.1111/pace.14495

M3 - Article

C2 - 35352363

SN - 0147-8389

VL - 45

SP - 605

EP - 611

JO - Pacing and Clinical Electrophysiology

JF - Pacing and Clinical Electrophysiology

IS - 5

ER -

Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this